• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 4:05:20 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLS alert in real time by email
    SC 13G/A 1 formsc13g-a.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Information Statement Pursuant to Rules 13d-1 and 13d-2

    Under the Securities Exchange Act of 1934

     

    (Amendment No.1 )*

     

    SELLAS Life Sciences Group, Inc.

     

    (Name of Issuer)

     

    Common Stock, par value $0.0001

     

    (Title of Class of Securities)

     

    81842T100

     

    (CUSIP Number)

     

    December 31, 2020

     

    (Date of Event which requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed;

     

    [  ] Rule 13d-1(b)

     

    [  ] Rule 13d-1(c)

     

    [X] Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 81842T100

    1. Names of Reporting Persons: Globis Capital Partners, L.P.
     

    I.R.S. Identification Nos. of above persons (entities only):

     

    2. Check the Appropriate Box if a member of a Group (See instructions)
      (a) [  ]
      (b)

    [X]

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization: Delaware

     

    Number of

    Shares

    Beneficially by

    Owned by Each

    Reporting

    Person with:

    5. Sole Voting Power: 0
       
    6. Shared Voting Power: 141,553
       
    7. Sole Dispositive Power: 0
       
    8.

    Shared Dispositive Power: 141,553

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person: 141,553
       
    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [  ]

     

    11.

    Percent of Class Represented by Amount in Row (9): 1.2%

     

    12. Type of Reporting Person (See Instructions) PN

     

     

     

     

    CUSIP No. 81842T100

    1. Names of Reporting Persons: Globis Capital Advisors, L.L.C.
     

    I.R.S. Identification Nos. of above persons (entities only):

     

    2. Check the Appropriate Box if a member of a Group (See instructions)
      (a) [  ]
      (b)

    [X]

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization: Delaware

     

    Number of

    Shares

    Beneficially by

    Owned by Each

    Reporting

    Person with:

    5. Sole Voting Power: 0
       
    6. Shared Voting Power: 141,553
       
    7. Sole Dispositive Power: 0
       
    8.

    Shared Dispositive Power: 141,553

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person: 141,553

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [  ]

     

    11.

    Percent of Class Represented by Amount in Row (9): 1.2%

     

    12. Type of Reporting Person (See Instructions) OO

     

     

     

     

    CUSIP No. 81842T100

    1. Names of Reporting Persons: Globis Capital Management, L.P.
     

    I.R.S. Identification Nos. of above persons (entities only):

     

    2. Check the Appropriate Box if a member of a Group (See instructions)
      (a) [  ]
      (b)

    [X]

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization: Delaware

     

    Number of

    Shares

    Beneficially by

    Owned by Each

    Reporting

    Person with:

    5. Sole Voting Power: 0
       
    6. Shared Voting Power: 141,553
       
    7. Sole Dispositive Power: 0
       
    8.

    Shared Dispositive Power: 141,553

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person: 141,553

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [  ]

     

    11.

    Percent of Class Represented by Amount in Row (9): 1.2%

     

    12. Type of Reporting Person (See Instructions) PN

     

     

     

     

    CUSIP No. 81842T100

    1. Names of Reporting Persons: Globis Capital, L.L.C.
     

    I.R.S. Identification Nos. of above persons (entities only):

     

    2. Check the Appropriate Box if a member of a Group (See instructions)
      (a) [  ]
      (b)

    [X]

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization: Delaware

     

    Number of

    Shares

    Beneficially by

    Owned by Each

    Reporting

    Person with:

    5. Sole Voting Power: 0
       
    6. Shared Voting Power: 141,553
       
    7. Sole Dispositive Power: 0
       
    8.

    Shared Dispositive Power: 141,553

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person: 141,553

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [  ]

     

    11.

    Percent of Class Represented by Amount in Row (9): 1.2%

     

    12. Type of Reporting Person (See Instructions) OO

     

     

     

     

    CUSIP No. 81842T100

    1. Names of Reporting Persons: Paul Packer
     

    I.R.S. Identification Nos. of above persons (entities only):

     

    2. Check the Appropriate Box if a member of a Group (See instructions)
      (a) [  ]
      (b)

    [X]

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization: United States

     

    Number of

    Shares

    Beneficially by

    Owned by Each

    Reporting

    Person with:

    5. Sole Voting Power: 0
       
    6. Shared Voting Power: 141,553
       
    7. Sole Dispositive Power: 0
       
      8.

    Shared Dispositive Power: 141,553

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person: 141,553

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [  ]

     

    11.

    Percent of Class Represented by Amount in Row (9): 1.2%

     

    12. Type of Reporting Person (See Instructions) IN

     

     

     

     

    Item 1.  

     

      (a) Name of Issuer:

     

    SELLAS Life Sciences Group, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    7 Times Square, Suite 2503
    New York, N.Y. 10036

     

    Item 2.  

     

      (a) Name of Person Filing:

     

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Act”):

     

      (i) Globis Capital Partners, L.P., a Delaware limited partnership (“Globis Partners”), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;
         
      (ii) Globis Capital Advisors, L.L.C., a Delaware limited liability company (“Globis Advisors”), serves as the general partner of Globis Partners, with respect to shares of Common Stock directly held by Globis Partners;
         
      (iii) Globis Capital Management, L.P., a Delaware limited partnership (the “Investment Manager”), which serves as investment manager to, and has investment discretion over the securities held by, Globis Partners, with respect to shares of Common Stock directly held by Globis Partners;
         
      (iv) Globis Capital, L.L.C., a Delaware limited liability company (“GC”), which serves as the general partner of the Investment Manager, with respect to shares of Common Stock directly held by Globis Partners;
         
      (v) Mr. Paul Packer (“Mr. Packer”), who is the Managing Member of Globis Advisors and GC, with respect to shares of Common Stock directly held by Globis Partners.

     

    Globis Partners, Globis Advisors, the Investment Manager, GC, and Mr. Packer are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

     

     

     

      (b) Address of Principal Business Office or, if none, Residence

     

    The principal office and business address of Globis Partners, Globis Advisors, the Investment Manager, GC and Mr. Packer is:

     

    805 Third Ave.

    15th Floor

    New York, New York 10022

     

      (c) Citizenship

     

    See Item 2(a) above and Item 4 of each cover page.

     

      (d) Title of Class of Securities

     

    Common Stock, par value $0.0001

     

      (e) CUSIP Number

     

    81842T100

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) 240.13d-2(b) or (c), check whether the person is filing is a:

     

    (a)[  ]     Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b)[  ]     Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)[  ]     Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d)[  ]     Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

    (e)[  ]     An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)

    [  ]     An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)

    [  ]     A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)[  ]     A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

    (i)[  ]     A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)[  ]     Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership:

     

      A. Globis Capital Partners, L.P.

     

      (a) Amount beneficially owned: 141,553

     

      (b) Percent of class: 1.2%

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or direct the vote: -0-

     

      (ii) Shared power to vote or direct the vote: 141,553

     

      (iii) Sole power to dispose or direct the disposition: -0-

     

      (iv) Shared power to dispose or direct the disposition: 141,553

     

      B. Globis Capital Advisors, L.L.C.

     

      (a) Amount beneficially owned: 141,553

     

      (b) Percent of class: 1.2%

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or direct the vote: -0-

     

      (ii) Shared power to vote or direct the vote: 141,553

     

      (iii) Sole power to dispose or direct the disposition: -0-

     

      (iv) Shared power to dispose or direct the disposition: 141,553

     

      C. Globis Capital Management, L.P.

     

      (a) Amount beneficially owned: 141,553

     

      (b) Percent of class: 1.2%

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or direct the vote: -0-

     

      (ii) Shared power to vote or direct the vote: 141,553

     

     

     

     

      (iii) Sole power to dispose or direct the disposition: -0-

     

      (iv) Shared power to dispose or direct the disposition: 141,553

     

      D. Globis Capital, L.L.C.

     

      (a) Amount beneficially owned: 141,553

     

      (b) Percent of class: 1.2%

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or direct the vote: -0-

     

      (ii) Shared power to vote or direct the vote: 141,553

     

      (iii) Sole power to dispose or direct the disposition: -0-

     

      (iv) Shared power to dispose or direct the disposition: 141,553

     

      E. Paul Packer

     

      (a) Amount beneficially owned: 141,553

     

      (b) Percent of class: 1.2%

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or direct the vote: -0-

     

      (ii) Shared power to vote or direct the vote: 141,553

     

      (iii) Sole power to dispose or direct the disposition: -0-

     

      (iv) Shared power to dispose or direct the disposition: 141,553

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following      [X]

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 12, 2021
      Date

     

      /s/ Paul Packer
      Paul Packer,
      individually and as managing member of:
      (a) Globis Capital Advisors, L.L.C.,
      for itself and as the general partner of Globis Capital Partners, L.P.; and (b) Globis Capital, L.L.C., for itself and as the general partner of Globis Capital Management, L.P., the Investment Manager of Globis Capital Partners, L.P.

     

     

    Get the next $SLS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SLS

    DatePrice TargetRatingAnalyst
    7/21/2021$18.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

      NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company's SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD. "We are thrilled to welcome Dr. Wang to our Scientific Advisory Board," said Dragan Cicic, MD, Senior Vice President, Chief Development Officer

      7/7/25 8:45:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

      Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

      6/24/25 12:52:00 PM ET
      $AUTL
      $CATX
      $INDP
      $ONCY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

      NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will be added to the Russell 3000® and Russell 2000® Indexes, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution. The Russell 3000® Index tracks the performance of the largest 3,000 publicly traded U.S. companies and serves as a broad benchmark for the U.S. equity market. The Russell 2000® Index, a subset of the Russell 3000®, measures the performance

      6/24/25 8:00:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      6/13/25 8:00:33 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wasman Jane bought $33,800 worth of shares (20,000 units at $1.69), increasing direct ownership by 192% to 30,400 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      6/2/25 4:42:07 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kalin Katherine Bach bought $36,000 worth of shares (20,000 units at $1.80), increasing direct ownership by 95% to 41,000 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      5/22/25 4:05:17 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    SEC Filings

    See more
    • SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      6/18/25 5:11:02 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by SELLAS Life Sciences Group Inc.

      DEFA14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      6/10/25 4:05:23 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      6/6/25 4:05:24 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      6/13/25 8:00:33 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wasman Jane bought $33,800 worth of shares (20,000 units at $1.69), increasing direct ownership by 192% to 30,400 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      6/2/25 4:42:07 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kalin Katherine Bach bought $36,000 worth of shares (20,000 units at $1.80), increasing direct ownership by 95% to 41,000 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      5/22/25 4:05:17 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on SELLAS Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of SELLAS Life Sciences with a rating of Overweight and set a new price target of $18.00

      7/21/21 11:28:03 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital initiated coverage on Solaris Resources with a new price target

      RBC Capital initiated coverage of Solaris Resources with a rating of Outperform and set a new price target of $18.00

      6/21/21 6:52:33 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SELLAS Life Sciences Group Inc.

      SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

      11/8/24 8:33:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by SELLAS Life Sciences Group Inc.

      SC 13G - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

      2/7/24 3:01:47 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

      2/16/21 10:08:07 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Leadership Updates

    Live Leadership Updates

    See more
    • SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

      NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company's SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD. "We are thrilled to welcome Dr. Wang to our Scientific Advisory Board," said Dragan Cicic, MD, Senior Vice President, Chief Development Officer

      7/7/25 8:45:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

      Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

      6/24/25 12:52:00 PM ET
      $AUTL
      $CATX
      $INDP
      $ONCY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

      NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of two distinguished oncology leaders to its Scientific Advisory Board (SAB). The new members – Philip C. Amrein, MD, and Alex Kentsis, MD, PhD bring decades of expertise in cancer research, clinical oncology, and translational medicine, further strengthening the company's strategic guidance as it advances its therapeutic pipeline. "We are honored to welcome Drs. Amrein and Kentsis to our Scientific Advisor

      6/5/25 8:45:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Financials

    Live finance-specific insights

    See more
    • SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022

      NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reminds the investment community that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), including the potential commercial opportunity for GPS in AML patients. The conference call and webcast will be held on Thursday, September 15, 2022, from 1:00 p.m. to 2:00 p.m. ET featuring remarks from Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer, and Robert Francomano, Chief Commer

      9/8/22 8:00:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

      NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update. "During the third quarter of 2021, in addition to continuing to enroll patients in the United States and Europe for our Phase 3 REGAL study of galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients, we also commenced clinical and regulatory preparations for a potential new Phase 2/3 study of GPS in AML patients following a bon

      11/12/21 8:45:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

      Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia (AML) Patients Highlights Continued Unmet Need and Expanded Market Opportunity for GPS Cash Position of $29.9 million as of June 30, 2021 To Host Virtual Investor Symposium on GPS on August 17, 2021 NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad ran

      8/12/21 4:22:52 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care